Taming Metabolic Disease

Jul 15, 2008

Over at In the Pipeline, Derek Lowe wonders what compounds might make good metabolic disease targets, harkening back to one put out there in 2002 by a company called Sumitomo Pharmaceuticals. He sees promise in CAMKK2, in that it's more upstream and involved in numerous pathways for regulation of appetite and glucose levels, including ghrelin, AMPK, and NPY.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

For Later in Life

Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.

At Altitude

Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.

Another Author on the List

Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.

PLOS Papers Take on Familial Disease Risk, COPD, More

In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.

Menu